Skip Nav Destination
Issues
1 February 2023
-
Cover Image
Cover Image
The cover shows a section of tertiary lymphoid structures from a patient with malignant pleural mesothelioma who had a major pathologic response to immune checkpoint blockade. Multiplexed imaging mass cytometry shows abundant mature TLSs containing germinal centers. CD20+ B cells are shown in dark blue, CD8+ T cells are marked in yellow, and CD4+ T cells are marked in magenta. For details, see the article by Lee and colleagues on page 548 of this issue. - PDF Icon PDF LinkTable of Contents
- PDF Icon PDF LinkEditorial Board
ISSN 1078-0432
EISSN 1557-3265
Highlights
CCR Translations
CCR Drug Updates
FDA Approval Summary: Mobocertinib for Metastatic Non–Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations
Elizabeth S. Duke; Liza Stapleford; Nicole Drezner; Anup K. Amatya; Pallavi S. Mishra-Kalyani; Yuan-Li Shen; Kimberly Maxfield; Jeanne Fourie Zirkelbach; Youwei Bi; Jiang Liu; Xinyuan Zhang; Hezhen Wang; Yuching Yang; Nan Zheng; Kelie Reece; Emily Wearne; Jacqueline J. Glen; Idara Ojofeitimi; Barbara Scepura; Abhilasha Nair; Rama Kamesh Bikkavilli; Soma Ghosh; Reena Philip; Richard Pazdur; Julia A. Beaver; Harpreet Singh; Martha Donoghue
Review
Clinical Trials: Targeted Therapy
Clinical Features Associated with Outcomes and Biomarker Analysis of Dabrafenib plus Trametinib Treatment in Patients with BRAF-Mutant Melanoma Brain Metastases
James S. Wilmott; Hussein Tawbi; Johnathan A. Engh; Nduka M. Amankulor; Brindha Shivalingam; Hiya Banerjee; Ismael A. Vergara; Hansol Lee; Peter A. Johansson; Peter M. Ferguson; Philippe Saiag; Caroline Robert; Jean-Jacques Grob; Lisa H. Butterfield; Richard A. Scolyer; John M. Kirkwood; Georgina V. Long; Michael A. Davies
Survival Outcomes, Digital TILs, and On-treatment PET/CT During Neoadjuvant Therapy for HER2-positive Breast Cancer: Results from the Randomized PREDIX HER2 Trial
Alexios Matikas; Hemming Johansson; Per Grybäck; Judith Bjöhle; Balazs Acs; Ceren Boyaci; Tobias Lekberg; Hanna Fredholm; Ellinor Elinder; Sara Margolin; Erika Isaksson-Friman; Ana Bosch; Henrik Lindman; Jamila Adra; Anne Andersson; Susanne Agartz; Mats Hellström; Ioannis Zerdes; Johan Hartman; Jonas Bergh; Thomas Hatschek; Theodoros Foukakis
Clinical Trials: Immunotherapy
A Phase II Window of Opportunity Study of Neoadjuvant PD-L1 versus PD-L1 plus CTLA-4 Blockade for Patients with Malignant Pleural Mesothelioma
Hyun-Sung Lee; Hee-Jin Jang; Maheshwari Ramineni; Daniel Y. Wang; Daniela Ramos; Jong Min Choi; Taylor Splawn; Monica Espinoza; Michelle Almarez; Leandria Hosey; Eunji Jo; Susan Hilsenbeck; Christopher I. Amos; R. Taylor Ripley; Bryan M. Burt
Safety and Efficacy of MEDI0457 plus Durvalumab in Patients with Human Papillomavirus–Associated Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Charu Aggarwal; Nabil F. Saba; Alain Algazi; Ammar Sukari; Tanguy Y. Seiwert; Missak Haigentz; Mercedes Porosnicu; Marcelo Bonomi; Jean Boyer; Mark T. Esser; Lily I. Cheng; Sonia Agrawal; Emily C. Jennings; Nicholas M. Durham; Karl Fraser; Delphine Lissa; Maozhen Gong; Natalia Ceaicovscaia; Amaya Gascó Hernández; Rakesh Kumar
Precision Medicine and Imaging
HER2 Copy Number and Resistance Mechanisms in Patients with HER2-positive Advanced Gastric Cancer Receiving Initial Trastuzumab-based Therapy in JACOB Trial
Filippo Pietrantonio; Paolo Manca; Sara Erika Bellomo; Simona Corso; Alessandra Raimondi; Enrico Berrino; Federica Morano; Cristina Migliore; Monica Niger; Lorenzo Castagnoli; Serenella Maria Pupa; Caterina Marchiò; Maria Di Bartolomeo; Eleonora Restuccia; Chiara Lambertini; Josep Tabernero; Silvia Giordano
[89Zr]Zr-DFO-girentuximab and [18F]FDG PET/CT to Predict Watchful Waiting Duration in Patients with Metastatic Clear-cell Renal Cell Carcinoma
Sarah R. Verhoeff; Sjoukje F. Oosting; Sjoerd G. Elias; Suzanne C. van Es; Sophie L. Gerritse; Lindsay Angus; Sandra Heskamp; Ingrid M.E. Desar; C. Willemien Menke-van der Houven van Oordt; Astrid A.M. van der Veldt; Anne I.J. Arens; Adrienne H. Brouwers; Bertha Eisses; Peter F.A. Mulders; Otto S. Hoekstra; Gerben J.C. Zwezerijnen; Winette T.A. van der Graaf; Erik H.J.G. Aarntzen; Wim J.G. Oyen; Carla M.L. van Herpen
Preoperative Neutrophil-to-Lymphocyte Ratio and a New Inflammatory Biomarkers Prognostic Index for Primary Retroperitoneal Sarcomas: Retrospective Monocentric Study
Marco Fiore; Silva Ljevar; Sandro Pasquali; Daniele Morelli; Dario Callegaro; Roberta Sanfilippo; Marta Barisella; Claudia Sangalli; Rosalba Miceli; Alessandro Gronchi
Translational Cancer Mechanisms and Therapy
Novel Lymphocyte-Independent Antitumor Activity by PD-1 Blocking Antibody against PD-1+ Chemoresistant Lung Cancer Cells
Ramona Rotolo; Valeria Leuci; Chiara Donini; Federica Galvagno; Annamaria Massa; Maria Chiara De Santis; Serena Peirone; Giovanni Medico; Martina Sanlorenzo; Igor Vujic; Loretta Gammaitoni; Marco Basiricò; Luisella Righi; Chiara Riganti; Iris Chiara Salaroglio; Francesca Napoli; Fabrizio Tabbò; Annapaola Mariniello; Elisa Vigna; Chiara Modica; Lorenzo D’Ambrosio; Giovanni Grignani; Riccardo Taulli; Emilio Hirsch; Matteo Cereda; Massimo Aglietta; Giorgio Vittorio Scagliotti; Silvia Novello; Paolo Bironzo; Dario Sangiolo
Humoral and Cellular Immune Responses against SARS-CoV-2 after Third Dose BNT162b2 following Double-Dose Vaccination with BNT162b2 versus ChAdOx1 in Patients with Cancer
Yana Debie; Jonas R.M. Van Audenaerde; Timon Vandamme; Lieselot Croes; Laure-Anne Teuwen; Lise Verbruggen; Greetje Vanhoutte; Elly Marcq; Lisa Verheggen; Debbie Le Blon; Bart Peeters; Maria E. Goossens; Pieter Pannus; Kevin K. Ariën; Sébastien Anguille; Annelies Janssens; Hans Prenen; Evelien L.J. Smits; Christof Vulsteke; Eva Lion; Marc Peeters; Peter A. van Dam
Letters to the Editor
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale within the United States of Bavencio® (avelumab), a pharmaceutical owned by Merck. If any resulting funds are received, they would not be used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.
RSS Feeds